2024-09-03T13:18:35-07:00 2023-12-31 461592906 Jones Simkins LLC 1011 West 400 North Suite 100 Logan UT 84321 990 2023-01-01 201829529 THE INSTITUTE FOR ETHNOMEDICINE INC DBA BRAIN CHEMISTRY LABS INST 8013756214 PO BOX 3464 JACKSON WY 83001 PAUL ALAN COX PHD Executive Dir. 2024-09-03 true true RICK E ARNELL CPA P01337052 4357521510 2023 2024-08-08 14:25:15Z PAUL ALAN COX PHD PO BOX 3464 JACKSON WY 83001 4099420 false X WWW.ETHNOMEDICINE.ORG X 2004 WY THE INSTITUTE FOR ETHNOMEDICINE SEARCHES FOR NEW CURES BY STUDYING PLANT MEDICINE AND PATTERNS OF WELLNESS AND DISEASE AMONG INDIGENOUS PEOPLE. 15 13 6 0 1747535 1916166 119771 30402 27125 92979 0 1894431 2039547 0 0 1220292 1142564 0 72046 1590718 1594540 2811010 2737104 -916579 -697557 4266357 3492810 612114 538100 3654243 2954710 THE INSTITUTE FOR ETHNOMEDICINE SEARCHES FOR NEW CURES BY STUDYING PLANT MEDICINE AND PATTERNS OF WELLNESS AND DISEASE AMONG INDIGENOUS PEOPLE. false false 2300679 30402 The Brain Chemistry Labs seeks to discover novel ways of preventing, diagnosing, and treating brain diseases. Our current focus is on progressive neurodegenerative diseases characterized by protein misfolds, including Alzheimers, ALS, Parkinsons, and Lewy Body disease. We are sponsoring a randomized, double-blinded, placebo-controlled Phase II clinical trial of the amino acid L-serine for the treatment of Mild Cognitive Impairment (a precursor of Alzheimers disease) at Houston Methodist Research Institute. We are currently raising funds for advanced clinical trials of L-serine for ALS, and a clinical trial for WY40687, a new drug we have discovered for advanced Parkinsons disease. We have discovered microRNA fingerprints, extracted from extracellular vesicles in the bloodstream, which are diagnostic for ALS as well as a novel metabolite which is diagnostic for early-stage Alzheimers disease. We have also discovered that naturally occurring small proteins, called cyclotides, may be useful as chemotherapy adjuvants for glioblastoma. 2300679 true true false false false false false false false false true false false false true false true false false false false false false false false false false false false true false false false false false false true false false false false false false false false false false true 15 0 false 6 true false false false false false false false 0 false false false false false false false X 15 13 false false false false false false false true true false false true true true true true true true false false X CINDY BUTERA 3077338377 PO BOX 3464 JACKSON WY 83001 PAUL ALAN COX PHD Executive Dir. 40.00 0.00 X X 293000 0 65014 SANDRA BANACK SENIOR SCIENTIST 40.00 0.00 197600 0 51674 MARILYN ASAY EXECUTIVE ASSISTAN 40.00 0.00 121200 0 48274 RACHAEL DUNLOP SR RESEARCH FELLOW 40.00 0.00 125238 0 39801 STEPHEN BOESCHENSTEIN Director 4.00 0.00 X 0 0 0 WILLIAM C EGAN III Board Chair 4.00 0.00 X X 0 0 0 GORDON DEANE Director 4.00 0.00 X 0 0 0 JOSEPH MERRILL Director 4.00 0.00 X 0 0 0 JAMES GORTER Director 4.00 0.00 X 0 0 0 PATRICK HENRY Director 4.00 0.00 X 0 0 0 DOUGLAS M KINNEY Director 4.00 0.00 X 0 0 0 JOHN WETHERELL Acting Chair 4.00 0.00 X X 0 0 0 MARION CHRISTOPH Director 4.00 0.00 X 0 0 0 ELIZABETH SUSAN SEVERSON board chair 4.00 0.00 X X 0 0 0 ROBERT PAULSON Director 4.00 0.00 X 0 0 0 DEREK CRAIGHEAD Director 4.00 0.00 X 0 0 0 BERTE HIRSCHFIELD Director 4.00 0.00 X 0 0 0 JOHN SMYTH Director 4.00 0.00 X 0 0 0 737038 204763 4 false true false Pillsbury Winthrop Shaw Pittman LLP PO BOX 742262 LOS ANGELES CA 90074 LEGAL SERVICES 194954 1 1916166 1916166 Research and Licensing 541700 30402 30402 30402 92581 92581 0 0 0 2060271 2059873 398 398 398 0 0 0 0 2039547 30402 92979 0 0 0 0 358014 280092 77922 60000 60000 499796 332813 166983 48440 33050 15390 126539 88881 37658 49775 35838 13937 0 259820 259820 30382 30382 0 0 0 34957 34957 0 67751 48265 19486 0 0 106308 106308 56543 56543 0 51762 39716 12046 0 0 262126 259505 2621 0 LABORATORY EXPENSES 724891 724891 0 2737104 2300679 364379 72046 441372 269263 2364804 2266886 200439 0 0 0 0 0 0 0 2142202 1698663 657826 443539 0 22300 22300 0 570016 481222 9600 9600 4266357 3492810 21224 27068 590890 511032 612114 538100 X 3654243 2954710 3654243 2954710 4266357 3492810 -697557 -1976 X false true X true false X 3017128 4856888 2974775 1747535 1916166 14512492 0 0 3017128 4856888 2974775 1747535 1916166 14512492 2940098 11572394 2154 153 43 28551 92581 123482 0 0 14635974 150173 0.79070 0.76790 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 781039 775264 5775 1361163 923399 437764 443539 Operating Lease Liability 511032 511032 2037571 -1976 -1976 2039547 2039547 2737104 2737104 2737104 X false false false false false false false false false MARILYN ASAY EXECUTIVE ASSISTAN 121200 12200 36074 169474 PAUL ALAN COX PHD Executive Dir. 293000 29300 35714 358014 RACHAEL DUNLOP SR RESEARCH FELLOW 125238 12624 27177 165039 SANDRA BANACK SENIOR SCIENTIST 197600 20000 31674 249274 Elizabeth Kinney Family Member 60000 Independent Contractor false Schedule L, Part V Supplemental Information Part IV line 1: Elizabeth Kinney is the spouse to board member Douglas Kinney and works as the Director of National Development in an independent contractor capacity. Form 990, Part VI, Section B, Line 11b A COPY OF THE FORM 990 IS ISSUED TO ALL BOARD MEMBERS FOR REVIEW BEFORE BEING FILED. Form 990, Part VI, Section B, Line 12c ANY DIRECTOR, DONOR, OR STAFF MEMBER WHO MAY HAVE A CONFLICT OF INTEREST WILL DISCLOSE THIS POTENTIAL CONFLICT TO THE APPROPRIATE SUPERVISOR, BE IT THE EXECUTIVE DIRECTOR OR CHAIRMAN OF THE BOARD. THE EXECUTIVE DIRECTOR WILL DISCLOSE ANY OF HIS OR HER CONFLICTS TO THE CHAIRMAN OF THE BAORD, AND THE CHAIRMAN WILL DISCLOSE ANY CONFLICTS OF INTEREST TO THE BOARD OF DIRECTORS. IN THE CASE OF A CONFICT OF INTEREST OF A DIRECTOR, THAT DIRECTOR WILL RECLUSE HIMSELF OR HERSELF FROM ANY VOTE ON THE PROPOSED ACTION. IN CASES OF RELATED PARTY TRANSACTIONS, THESE TRANSACTIONS WILL BE APPROVED IN ADVANCE IN WRITING BY EITHER THE EXECTUIVE DIRECTOR OR THE CHAIRMAN OF THE BOARD AND FLAGGED FOR THE EXTERNAL AUDITORS TO EXAMEN DURING THE ANNUAL AUDIT. DIRECTORS ARE ASKED ANNUALLY TO DISCLOSE ANY CONFLICTS OF INTEREST TO THE CHAIR, AND THE CHAIR WILL MONITOR AND ENFORCE COMPLIANCE WITH THIS POLICY. Form 990, Part VI, Section B, Line 15a THE COMPENSATION OF THE CEO AND EXECUTIVE DIRECTOR WILL BE DETERMINED BY A COMMITTEE COMPOSED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS SELECTED BY THE CHAIRMAN. TO ASSIST IN DETERMINING COMPENSATION, THE CEO WILL BE ASKED TO PROVIDE COMPARABLE SALARY DATA FOR OTHER PROFESSIONALS OF SIMILAR EDUCATION, TRAININGS, AND RESPONSIBILITY FROM UNIVERSITIES AND OTHER MEDICAL RESEARCH FACILITIES. THE ANNUAL COMPENSATION WILL BE DETERMINED BY THE COMPENSATION COMMITTEE AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISIONS OF THE COMMITTEE WILL BE RETAINED BY THE CHAIRMAN OF THE BOARD. Form 990, Part VI, Section C, Line 19 ALL GOVERNING DOCUMENTS, POLICIES, AND FINANCIAL STATEMENTS ARE MADE AVAILABLE UPON REQUEST.